Generation Bio Co (NASDAQ:GBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Generation Bio Co (GBIO)
Generation Bio Co (NASDAQ:GBIO) has a market capitalization of $35.98 Million ($35.98 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23231 globally and #5075 in its home market, demonstrating a -4.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Generation Bio Co's stock price $5.34 by its total outstanding shares 6738545 (6.74 Million). Also see Generation Bio Co (GBIO) total assets for a full breakdown of the balance sheet.
Generation Bio Co Market Cap History: 2020 to 2026
Generation Bio Co's market capitalization history from 2020 to 2026. Data shows change from $191.04 Million to $35.98 Million (-23.71% CAGR). Also see GBIO operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Generation Bio Co is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #665 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2196 of 3165 |
Weight: Generation Bio Co's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Generation Bio Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Generation Bio Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GBIO stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.36x
Generation Bio Co's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $26.48 Million | $880.00K | -$132.10 Million | 30.09x | N/A |
| 2023 | $11.12 Million | $5.90 Million | -$126.61 Million | 1.88x | N/A |
| 2024 | $7.14 Million | $19.89 Million | -$131.67 Million | 0.36x | N/A |
Competitor Companies of GBIO by Market Capitalization
Companies near Generation Bio Co in the global market cap rankings as of September 18, 2026. Review GBIO tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Generation Bio Co by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Generation Bio Co Historical Marketcap From 2020 to 2026
Between 2020 and today, Generation Bio Co's market cap moved from $191.04 Million to $ 35.98 Million, with a yearly change of -23.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.98 Million | -5.99% |
| 2025 | $38.27 Million | +435.85% |
| 2024 | $7.14 Million | -35.76% |
| 2023 | $11.12 Million | -58.02% |
| 2022 | $26.48 Million | -44.49% |
| 2021 | $47.71 Million | -75.03% |
| 2020 | $191.04 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Generation Bio Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.98 Million USD |
| MoneyControl | $35.98 Million USD |
| MarketWatch | $35.98 Million USD |
| marketcap.company | $35.98 Million USD |
| Reuters | $35.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more